Pinder R M
Acta Psychiatr Scand Suppl. 1985;320:1-9. doi: 10.1111/j.1600-0447.1985.tb08068.x.
Mianserin is a tetracyclic antidepressant whose postulated mechanism of action involves release of noradrenaline mediated via cortical alpha 2-adrenergic autoreceptor blockade. This property resides stereoselectively in the S(+)-enantiomer of mianserin, which is also more potent in behavioural tests indicative of antidepressant activity, and in the reversal of clonidine-induced effects. Cortical receptor binding studies have indicated that although a similar stereoselectivity prevails for the inhibition of both alpha 2-binding (clonidine) and alpha 1-binding (prazosin), mianserin and its enantiomers are more potent antagonists at alpha 2- than at alpha 1-binding sites. However, no stereoselectivity is apparent for the antagonism of cortical alpha 2-heteroreceptors controlling serotonin release. Following chronic administration, (+/-)- and S(+)-mianserin, but not the R(-)-enantiomer, produce functional supersensitivity at alpha 2-autoreceptors which is unaccompanied by changes in clonidine binding. Neither mianserin nor its enantiomers alter the sensitivity of alpha 2-heteroreceptors following chronic administration. Like mianserin and its S(+)-enantiomer, but unlike R(-)-mianserin and the 8-hydroxy metabolite, the desmethyl metabolite inhibits noradrenaline uptake in vitro. 8-hydroxymianserin and, to a lesser extent, desmethylmianserin release noradrenaline from cortical slices via alpha 2-autoreceptor antagonism, but only the 8-hydroxy metabolite blocks alpha 2-autoreceptors and alpha 2-heteroreceptors in synaptosomal preparations. It is likely that S(+)-mianserin, desmethylmianserin, and 8-hydroxymianserin contribute substantially to the overall facilitating effect of mianserin on noradrenergic transmission in vivo. As yet it is unclear whether this effect is exclusively responsible for the antidepressant activity of mianserin or whether the stereoselectivity also shown by the mianserin enantiomers towards serotonin receptors plays a complementary role.
米安色林是一种四环类抗抑郁药,其假定的作用机制涉及通过皮质α2-肾上腺素能自身受体阻断介导去甲肾上腺素的释放。这种特性立体选择性地存在于米安色林的S(+)-对映体中,在指示抗抑郁活性的行为测试以及可乐定诱导效应的逆转中,该对映体也更有效。皮质受体结合研究表明,虽然在抑制α2-结合(可乐定)和α1-结合(哌唑嗪)方面存在类似的立体选择性,但米安色林及其对映体在α2-结合位点比在α1-结合位点是更有效的拮抗剂。然而,对于控制5-羟色胺释放的皮质α2-异受体的拮抗作用,没有明显的立体选择性。长期给药后,(+/-)-米安色林和S(+)-米安色林,但不是R(-)-对映体,在α2-自身受体处产生功能性超敏反应,且可乐定结合无变化。长期给药后,米安色林及其对映体均不改变α2-异受体的敏感性。与米安色林及其S(+)-对映体一样,但与R(-)-米安色林和8-羟基代谢物不同,去甲基代谢物在体外抑制去甲肾上腺素摄取。8-羟基米安色林以及程度较轻的去甲基米安色林通过α2-自身受体拮抗作用从皮质切片释放去甲肾上腺素,但只有8-羟基代谢物在突触体制剂中阻断α2-自身受体和α2-异受体。S(+)-米安色林、去甲基米安色林和8-羟基米安色林很可能对米安色林在体内对去甲肾上腺素能传递的总体促进作用有很大贡献。目前尚不清楚这种作用是否完全是米安色林抗抑郁活性的原因,或者米安色林对映体对5-羟色胺受体也表现出的立体选择性是否起互补作用。